November 1st 2024
Panelists discuss the currently available chimeric antigen receptor T-cell therapies for early relapse multiple myeloma, examining their place within the treatment paradigm and how factors such as product type (cilta-cel vs ide-cel) and high-risk features (such as minimal residual disease positivity post induction and extramedullary disease) influence clinical decision-making.
Panelists discuss the key disease and patient factors considered when choosing between triplet and quadruplet induction regimens for patients with transplant-ineligible multiple myeloma, as well as the unmet needs that persist in the treatment landscape for both transplant-eligible and ineligible populations.
October 25th 2024
Panelists discuss the CEPHEUS trial results for newly diagnosed patients who are not transplant eligible, highlighting key takeaways. They also compare the CEPHEUS data with other quadruplet regimens in the non–transplant-eligible space, such as Isa-VRd.
Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.
October 18th 2024
Panelists discuss whether daratumumab quadruplet induction regimens should be considered the new standard of care for newly diagnosed transplant-eligible patients and explore scenarios in which a triplet induction regimen might still be appropriate. They also review the findings from the ISKIA and GMMG-CONCEPT trials, including considerations for using isatuximab-carfilzomib (IsaKRd) over D-VRd.
Panelists discuss the findings of the PERSEUS trial and the recent cytogenetic risk analysis for patients with newly diagnosed transplant-eligible multiple myeloma. They then explore the CASSIOPEIA trial and its implications regarding daratumumab quadruplet induction regimens.
June 16th 2022
Closing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.
Luciano Costa, MD, and Adriana Rossi, MD, consider the possibility of earlier-line bispecific and CAR T-cell therapies in multiple myeloma.
June 9th 2022
In light of emerging bispecific and CAR T-cell therapies in multiple myeloma, experts consider how they might optimally sequence treatment.
Comprehensive discussion on the MonumenTAL-1 trial of talquetamab, a GPRC5D- and CD3-targeted agent, in the setting of relapsed/refractory multiple myeloma.
June 2nd 2022
Moving on to the second clinical scenario of multiple myeloma, Luciano Costa, MD, details his care of a heavily pretreated patient.
Expert perspectives on the MajesTEC-1 trial, a study of BCMA- and CD3-targeted agent teclistamab in relapsed/refractory multiple myeloma.
May 26th 2022
Shared insight on factors that help to determine optimal therapy for patients diagnosed with triple-class refractory multiple myeloma.
Expert hematologist-oncologist Adriana Rossi, MD, shares a real-world patient scenario of triple-class refractory multiple myeloma managed with novel bispecific antibody therapy.